Open AccessHuman Insulin (Entuzity KwikPen)
Author(s) -
Reimbursement Team
Publication year - 2021
Publication title -
canadian journal of health technologies
Language(s) - English
Resource type - Journals
ISSN - 2563-6596
DOI - 10.51731/cjht.2021.169
Subject(s) - reimbursement , glycemic , human insulin , insulin , medicine , diabetes mellitus , drug , subcutaneous injection , drug class , intensive care medicine , pharmacology , business , endocrinology , political science , law , health care
CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec.
This review assesses human biosynthetic insulin (Entuzity KwikPen), 500 units/mL subcutaneous insulin injection, human biosynthetic, solution for injection
Indication: Entuzity is indicated to improve glycemic control in adults and children with diabetes mellitus requiring more than 200 units of insulin per day
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom